813466-05-6

Basic information

• Product Name: 1H-Imidazole-5-carboxylic acid, 1-[(1R)-1-(4-iodophenyl)ethyl]-, methyl ester
• CAS NO: 813466-05-6
• Molecular Formula: C13H13IN2O2
• Molecular Weight: 356.163
• Mol File: 813466-05-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1H-Imidazole-5-carboxylic acid, 1-[(1R)-1-(4-iodophenyl)ethyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-5-carboxylic acid, 1-[(1R)-1-(4-iodophenyl)ethyl]-, methyl ester(813466-05-6)
• EPA Substance Registry System: 1H-Imidazole-5-carboxylic acid, 1-[(1R)-1-(4-iodophenyl)ethyl]-, methyl ester(813466-05-6)

Safety Data

• Hazardous Substances Data: 813466-05-6(Hazardous Substances Data)

Upstream product

• 68120-56-9 1-(4-iodophenyl)ethanol 
• 103966-63-8 (+/-)-1-(4-iodophenyl)ethyl acetate 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 1586033-65-9 N-(α-methyl-4-iodobenzyl)-N-formylglycine methyl ester 
• 439811-16-2 C₁₀H₉F₃INO 
• 1586033-68-2 N-(α-methyl-4-iodobenzyl)-2-mercaptoimidazole-5-carboxylic acid methyl ester 
• 1586033-67-1 N-(α-methyl-4-iodobenzyl)-N-formyl-C-formylglycine methyl ester 
• 1586033-63-7 N-(α-methyl-4-iodobenzyl)glycine methyl ester 
• 150085-44-2 R-(+)-1-(4-iodophenyl)ethylamine 
• 813466-07-8 (S)-1-(4-iodophenyl)ethyl chloroacetate 
• 813466-04-5 (+/-)-1-(4-iodophenyl)ethyl chloroacetate 
• 220089-24-7 (R)-(+)-1-(4-iodophenyl)ethanol 
• 868054-61-9 (S)-1-(4-iodophenyl)ethyl acetate 
• 13329-40-3 4-Iodoacetophenone 

Downstream Products

• 1586033-71-7 (R)-1-[1-(4-trimethylstannylphenyl)ethyl]-1H-imidazole-5-carboxylic acid ethylmethylamide 
• 1588490-10-1 (R)-1-[1-(4-trimethylstannylphenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinylamide 
• 1588490-09-8 (R)-1-[1-(4-iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinylamide 
• 1423567-15-0 (R)-(+)-[1-(4-iodophenyl)ethyl]-1H-imidazole 
• 1434047-36-5 C₁₃H₁₄IN₃O 
• 1082736-75-1 C₁₄H₁₄N₂O₃ 

Relevant articles and documents

Radiopharmaceutical products for diagnosis and therapy of renal carcinoma

A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic

New selective inhibitors of steroid 11β-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues

Derivatives of etomidate were evaluated as inhibitors of adrenal steroid 11β-hydroxylations. Stereoselective coupling by Mitsunobu produced chirally pure analogues to study the effect of configuration, modification of the ester, and substitution in the phenyl ring, with the aim to probe specific sites for introducing a radionuclide. Iodophenyl metomidate (IMTO) labeled with iodine-131 served as radioligand for structure-affinity relationship studies. We have characterized the kinetic parameters of specific 131I-IMTO binding on rat adrenal membranes and used the displacement of 131I-IMTO binding to evaluate functionalized MTO analogues. Our results indicated that (1) (R)-configuration is essential for high affinity, (2) highest potency resides in the ethyl, 2-propyl, and 2-fluoroethyl esters, and (3) substitution of the phenyl ring is well tolerated. The clinically used inhibitors metyrapone and ketoconazole inhibited 131I-IMTO binding with low affinity. Incubation of selected analogues with human adrenocortical NCI-h295 cells demonstrated a high correlation with the inhibitory effect on cortisol secretion.

Radiolabelled phenylethyl imidazole caboxylic acid ester derivatives

Halogenated carboxylic ester derivatives of phenylethyl imidazole, and their method of preparation are disclosed. Radio-halogenated forms of these compounds are ideally suited for positron-imaging of the adrenal glands, as it is known that these compounds demonstrate a selective and high rate of accumulation in the adrenals. The method of preparing these derivatives proceeds by the conversion of a stable, non-radioactive intermediate having trialkylstannyl leaving groups. These intermediates are efficiently converted to the corresponding halogenated forms by substitution of the trialkylstannyl group with the halogen or radiohalogen.